S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
66,000% upside on tiny biotech? (Ad)
How major US stock indexes fared Friday, 2/23/2024
MarketBeat Week in Review – 2/19 - 2/23
66,000% upside on tiny biotech? (Ad)
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Closing prices for crude oil, gold and other commodities
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
Mike Tyson’s Wisdom: Life, Planning, and Resilience
White House, tribal leaders hail 'historic' deal to restore salmon runs in Pacific Northwest
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
66,000% upside on tiny biotech? (Ad)
How major US stock indexes fared Friday, 2/23/2024
MarketBeat Week in Review – 2/19 - 2/23
66,000% upside on tiny biotech? (Ad)
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Closing prices for crude oil, gold and other commodities
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
Mike Tyson’s Wisdom: Life, Planning, and Resilience
White House, tribal leaders hail 'historic' deal to restore salmon runs in Pacific Northwest
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
66,000% upside on tiny biotech? (Ad)
How major US stock indexes fared Friday, 2/23/2024
MarketBeat Week in Review – 2/19 - 2/23
66,000% upside on tiny biotech? (Ad)
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Closing prices for crude oil, gold and other commodities
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
Mike Tyson’s Wisdom: Life, Planning, and Resilience
White House, tribal leaders hail 'historic' deal to restore salmon runs in Pacific Northwest
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
66,000% upside on tiny biotech? (Ad)
How major US stock indexes fared Friday, 2/23/2024
MarketBeat Week in Review – 2/19 - 2/23
66,000% upside on tiny biotech? (Ad)
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Closing prices for crude oil, gold and other commodities
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
Mike Tyson’s Wisdom: Life, Planning, and Resilience
White House, tribal leaders hail 'historic' deal to restore salmon runs in Pacific Northwest

Apellis Pharmaceuticals (APLS) Competitors

$68.47
+0.88 (+1.30%)
(As of 02/23/2024 ET)

APLS vs. ELAN, JAZZ, CYTK, CERE, ITCI, ASND, ROIV, IONS, BBIO, and UTHR

Should you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include Elanco Animal Health (ELAN), Jazz Pharmaceuticals (JAZZ), Cytokinetics (CYTK), Cerevel Therapeutics (CERE), Intra-Cellular Therapies (ITCI), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Ionis Pharmaceuticals (IONS), BridgeBio Pharma (BBIO), and United Therapeutics (UTHR). These companies are all part of the "pharmaceutical preparations" industry.

Apellis Pharmaceuticals vs.

Elanco Animal Health (NYSE:ELAN) and Apellis Pharmaceuticals (NASDAQ:APLS) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, community ranking, media sentiment and institutional ownership.

Elanco Animal Health has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.

Elanco Animal Health has higher revenue and earnings than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elanco Animal Health$4.42B1.83-$78M-$2.32-7.06
Apellis Pharmaceuticals$75.42M107.58-$652.17M-$5.25-13.04

Apellis Pharmaceuticals received 178 more outperform votes than Elanco Animal Health when rated by MarketBeat users. Likewise, 67.25% of users gave Apellis Pharmaceuticals an outperform vote while only 54.24% of users gave Elanco Animal Health an outperform vote.

CompanyUnderperformOutperform
Elanco Animal HealthOutperform Votes
128
54.24%
Underperform Votes
108
45.76%
Apellis PharmaceuticalsOutperform Votes
306
67.25%
Underperform Votes
149
32.75%

In the previous week, Apellis Pharmaceuticals had 6 more articles in the media than Elanco Animal Health. MarketBeat recorded 14 mentions for Apellis Pharmaceuticals and 8 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 0.64 beat Apellis Pharmaceuticals' score of 0.23 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Elanco Animal Health
2 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Apellis Pharmaceuticals
5 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Elanco Animal Health has a net margin of -26.18% compared to Elanco Animal Health's net margin of -222.16%. Apellis Pharmaceuticals' return on equity of 6.99% beat Elanco Animal Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Elanco Animal Health-26.18% 6.99% 3.22%
Apellis Pharmaceuticals -222.16%-209.10%-69.82%

95.3% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 90.4% of Apellis Pharmaceuticals shares are owned by institutional investors. 6.4% of Elanco Animal Health shares are owned by insiders. Comparatively, 7.5% of Apellis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Elanco Animal Health presently has a consensus price target of $15.64, suggesting a potential downside of 4.44%. Apellis Pharmaceuticals has a consensus price target of $75.93, suggesting a potential upside of 10.90%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than Elanco Animal Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Elanco Animal Health
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Apellis Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.87

Summary

Apellis Pharmaceuticals beats Elanco Animal Health on 10 of the 19 factors compared between the two stocks.


Get Apellis Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APLS vs. The Competition

MetricApellis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$8.11B$6.73B$5.10B$7.52B
Dividend YieldN/A2.74%2.85%3.86%
P/E Ratio-13.0410.40190.4816.11
Price / Sales107.58196.023,057.1267.32
Price / CashN/A18.6199.3755.40
Price / Book44.464.614.394.60
Net Income-$652.17M$156.87M$114.40M$207.21M
7 Day Performance-0.45%1.01%0.90%-1.07%
1 Month Performance2.93%10.73%7.28%3.57%
1 Year Performance2.67%4.09%10.69%5.52%

Apellis Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ELAN
Elanco Animal Health
1.78 of 5 stars
$16.15
-0.7%
$15.64
-3.1%
+35.8%$7.96B$4.42B-6.969,000Upcoming Earnings
JAZZ
Jazz Pharmaceuticals
4.9611 of 5 stars
$126.36
-0.3%
$195.90
+55.0%
-9.5%$7.96B$3.79B143.592,800Upcoming Earnings
CYTK
Cytokinetics
3.3537 of 5 stars
$76.89
flat
$73.94
-3.8%
+81.1%$7.54B$94.59M-13.93409Upcoming Earnings
CERE
Cerevel Therapeutics
0.6148 of 5 stars
$41.04
-3.6%
$39.64
-3.4%
+54.0%$7.40BN/A-16.42321Upcoming Earnings
High Trading Volume
ITCI
Intra-Cellular Therapies
4.3764 of 5 stars
$73.70
-2.6%
$80.42
+9.1%
+47.2%$7.09B$250.31M-45.78561Earnings Report
Analyst Report
Analyst Revision
News Coverage
ASND
Ascendis Pharma A/S
1.7612 of 5 stars
$156.76
+0.2%
$158.29
+1.0%
+38.7%$9.05B$288.08M-16.95879Positive News
ROIV
Roivant Sciences
4.2803 of 5 stars
$11.54
-0.4%
$16.50
+43.0%
+41.1%$9.28B$123.24M2.22904Positive News
IONS
Ionis Pharmaceuticals
3.9222 of 5 stars
$44.35
-0.2%
$49.80
+12.3%
+23.6%$6.36B$587M-15.45796Earnings Report
Analyst Report
News Coverage
BBIO
BridgeBio Pharma
4.4575 of 5 stars
$35.95
-3.4%
$42.00
+16.8%
+191.3%$6.25B$77.65M-9.22392Earnings Report
Analyst Report
News Coverage
Gap Up
UTHR
United Therapeutics
4.9897 of 5 stars
$214.16
-0.3%
$292.80
+36.7%
-8.6%$10.06B$1.94B11.80985Earnings Report
Analyst Report
Analyst Revision
News Coverage

Related Companies and Tools

This page (NASDAQ:APLS) was last updated on 2/24/2024 by MarketBeat.com Staff